Inclusion Criteria

Inclusion Criteria

- Subject is ≥ 18 years of age at date of enrolment

- Histologically or cytologically confirmed carcinoma of colon or rectum

- Subject with metastatic carcinoma of colon or rectum

- Confirmed wild-type KRAS status of tumour

- Subjects whose care will be managed primarily by the enrolling physician and/ or all
records will be available

- Tumour assessment (ie, CT/MRI) within 12 weeks (84 days) prior to first Vectibix®
infusion.

- Subjects treated with at least one infusion of Vectibix® in combination with
chemotherapy a maximum of 42 days before entering study: first-line in combination
with FOLFOX or second-line in combination with FOLFIRI in subjects who have received
first-line fluoropyrimidine-based chemotherapy (excluding irinotecan) for treatment
of wild-type KRAS mCRC per approved prescribing information

- Subject or subject's legally acceptable representative has provided informed consent
(for countries where required per local regulations)

Exclusion Criteria

- Ongoing or planned concurrent participation in any clinical study involving
Investigational Product that has not been approved by the European Medicines Agency
for any indication

- Ongoing or planned concurrent participation in any clinical study where the dosing of
Vectibix® is determined by the protocol (participation in clinical trials on an
approved drug and observational trials are permitted but these cannot mandate how
mCRC should be treated)